Response to comments on the Scientific Opinion of the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) on the scientific substantiation of a health claim related to Nutrimune® and immune defence against pathogens in the gastrointestinal and

First published in EFSA Supporting Publications:
11 July 2017
Issued
29 June 2017
Type
Technical Report Post 11
Abstract

Following a request from the European Commission, EFSA was asked to review the scientific comments received on the Scientific Opinion of the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) on the scientific substantiation of a health claim related to Nutrimune® and immune defence against pathogens in the gastrointestinal and upper respiratory tracts pursuant to Article 14 of Regulation (EC) No 1924/2006. Comments originating from the applicant (H.J. Heinz Supply Chain Europe B.V.) were submitted to EFSA via the European Commission Services. EFSA has reviewed the comments with the contribution of the chair of the NDA Working Group on Claims, the chair of the NDA Panel and one expert member of the NDA Panel. In its opinion adopted on 14 December 2016, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) concluded that the scientific evidence is insufficient to establish a cause and effect relationship between the consumption of Nutrimune® and immune defence against pathogens in the gastrointestinal and upper respiratory tracts. The comments received do not require any change in the conclusions of the NDA Panel. Following a request from the European Commission, EFSA was asked to review the scientific comments received on the Scientific Opinion of the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) on the scientific substantiation of a health claim related to Nutrimune® and immune defence against pathogens in the gastrointestinal and upper respiratory tracts pursuant to Article 14 of Regulation (EC) No 1924/2006. Comments originating from the applicant (H.J. Heinz Supply Chain Europe B.V.) were submitted to EFSA via the European Commission Services. EFSA has reviewed the comments with the contribution of the chair of the NDA Working Group on Claims, the chair of the NDA Panel and one expert member of the NDA Panel. In its opinion adopted on 14 December 2016, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) concluded that the scientific evidence is insufficient to establish a cause and effect relationship between the consumption of Nutrimune® and immune defence against pathogens in the gastrointestinal and upper respiratory tracts. The comments received do not require any change in the conclusions of the NDA Panel.

Question Number